
Opus Genetics (IRD) Stock Forecast & Price Target
Opus Genetics (IRD) Analyst Ratings
Bulls say
Opus Genetics Inc is positioned favorably due to positive topline outcomes from the Phase 3 trials for phentolamine, showcasing significant efficacy with 17.3% of patients achieving a notable improvement in visual acuity compared to 9.2% for placebo, which underscores the potential market appeal of the therapy. The upcoming supplemental New Drug Application (sNDA) submission for presbyopia is anticipated in the second half of 2025, aligning with the company's strategic development timeline and market entry objective. Additionally, the collaboration with Viatris enhances Opus's ability to effectively develop and commercialize phentolamine, thereby reinforcing its growth potential in the ophthalmic therapeutics space.
Bears say
Opus Genetics faces significant risks that impact its investment thesis and financial outlook, primarily due to the possibility of its products failing to meet peak commercial revenue estimates, which may stem from limited market size, low penetration rates, or unfavorable pricing dynamics. Additionally, the company may struggle to secure the necessary capital resources required to fund ongoing operations, thereby hindering further program development and commercialization efforts. These fundamental concerns reflect a broader uncertainty about the viability and profitability of its pipeline, which includes gene therapies and ophthalmic solutions critical for its financial success.
This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.
Opus Genetics (IRD) Analyst Forecast & Price Prediction
Start investing in Opus Genetics (IRD)
Order type
Buy in
Order amount
Est. shares
0 shares